Efficacy of canagliflozin (INVOKANA) versus dapagliflozin in patients with type 2 diabetes: A real world study
Phase of Trial: Phase IV
Latest Information Update: 04 May 2018
Price : $35 *
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 04 May 2018 New trial record
- 27 Apr 2018 Primary endpoint of proportion of patients who achieved the HEDIS-recommended A1C goal of less than 8.0 percent has been met, according to results presented in a Janssen Pharmaceuticals Media Release.
- 27 Apr 2018 Results presented in a Janssen Pharmaceuticals Media Release.